[A23-120] Cannabidiol (Lennox Gastaut syndrome) – Benefit assessment according to §35a Social Code Book V
Last updated 01.03.2024
Project no.:
A23-120
Commission:
Commission awarded on 04.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Adjunctive therapy in patients 2 years of age and older with seizures associated with Lennox-Gastaut syndrome
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A23-120_en